FY2028 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for Invivyd in a note issued to investors on Monday, June 15th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.25 per share for the year, up from their previous estimate of $0.24. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Invivyd’s FY2029 earnings at $0.68 EPS and FY2030 earnings at $1.21 EPS.

A number of other research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Tuesday, June 9th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.00.

Invivyd Trading Up 12.8%

IVVD opened at $0.87 on Tuesday. Invivyd has a 1-year low of $0.48 and a 1-year high of $3.07. The stock has a market capitalization of $255.90 million, a price-to-earnings ratio of -2.80 and a beta of 0.63. The business has a 50 day moving average of $1.31 and a 200-day moving average of $1.76.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The business had revenue of $13.74 million during the quarter, compared to the consensus estimate of $18.04 million.

Hedge Funds Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp increased its stake in shares of Invivyd by 9.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock valued at $139,000 after acquiring an additional 8,800 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Invivyd by 54.3% in the 1st quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock valued at $35,000 after acquiring an additional 9,568 shares during the last quarter. Courier Capital LLC bought a new stake in shares of Invivyd in the 4th quarter valued at about $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Invivyd in the 4th quarter valued at about $27,000. Finally, DRW Securities LLC bought a new stake in shares of Invivyd in the 4th quarter valued at about $27,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.